Ticagrelor Tablet
Product Images NDC 72516-017

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 72516-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oryza Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
A Kaplan-Meier cumulative incidence curve comparing Ticagrelor 90 mg and Clopidogrel over 360 days from first study drug dose. The y-axis shows cumulative percentage, and the x-axis shows days. The graph includes patient numbers at risk at various time points and event rates for both drugs.*
FDA Label Image

Fiigure_2 (Figure 2)

Fiigure_2 (Figure 2)
A vertical bar chart showing the percentage of patients who had an event following CABG surgery over a period of 1 to 8 or more days. The chart compares two groups labeled T and C for each day, with percentages on the vertical axis and days on the horizontal axis. Numeric data below the chart shows patient counts for both groups on each day.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure diagram of Ticagrelor showing its molecular arrangement with atom connections, including fluorine atoms and functional groups as part of the molecule.*
FDA Label Image

Figure_8 (Figure 08)

Figure_8 (Figure 08)
A chart titled 'Mean effect and 90% CI' showing the impact of various interacting drugs on Ticagrelor's pharmacokinetics, including Cmax and AUC values represented by square and triangle markers respectively. The chart compares changes relative to reference values for drugs like Ketoconazole, Diltiazem, Rifampin, Aspirin, Desmopressin, Heparin, Enoxaparin, Cyclosporine, Morphine, and Fentanyl, along with dosing recommendations or adjustments.*
FDA Label Image

Figure_10 (Figure 10)

Figure_10 (Figure 10)
A Kaplan-Meier curve comparing the cumulative percentage of events over 360 days for Ticagrelor 90 mg (solid line) versus Clopidogrel (dashed line). The chart shows days from randomization on the x-axis and cumulative percentage on the y-axis, with a risk table below and summary statistics including number of patients, event rates, hazard ratio, confidence interval, and p-value displayed in a legend box.*
FDA Label Image

Figure_11 (Figure 11)

Figure_11 (Figure 11)
A forest plot chart comparing Ticagrelor and Clopidogrel treatment effects across various patient characteristics, including geographic region, aspirin dose, treatment approach, PCI timing, CABG status, diabetes history, prior TIA/stroke, glycoprotein inhibitor use, age groups, sex, and race. The chart shows hazard ratios with 95% confidence intervals indicating relative effectiveness between the two drugs.*
FDA Label Image

Figure_12 (Figure 12)

Figure_12 (Figure 12)
A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different ASA dose categories (>=300 mg, 100-<300 mg, <=100 mg) in US and Non-US regions. The plot shows relative effectiveness on a logarithmic scale, indicating where Ticagrelor or Clopidogrel is favored.*
FDA Label Image

Figure_13 (Figure 13)

Figure_13 (Figure 13)
A Kaplan-Meier cumulative percent curve chart showing event rates over days from randomization for Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo groups. The chart includes cumulative percentages on the vertical axis and days (up to approximately 1320) on the horizontal axis, with curves for each group and a risk table for patient counts at various time points.*
FDA Label Image

Figure_14 (Figure 14)

Figure_14 (Figure 14)
A forest plot chart displaying hazard ratios (HR) with 95% confidence intervals (CI) comparing ticagrelor versus placebo across various patient characteristics and subgroups. The vertical line represents no treatment difference (HR=1), with ticagrelor effects shown on the left, placebo effects on the right. Subgroups include age, sex, race, weight, BMI, geographic region, medical history, and other clinical factors.*
FDA Label Image

Figure_15 (Figure 15)

Figure_15 (Figure 15)
Kaplan-Meier cumulative event percentage plot comparing Ticagrelor versus placebo over approximately 54 months from randomization. The solid line represents Ticagrelor, and the dashed line represents placebo, showing cumulative percentage on the y-axis and months on the x-axis. A table below shows number of subjects at risk each month for both groups.*
FDA Label Image

Figure_16 (Figure 16)

Figure_16 (Figure 16)
A forest plot illustrating the hazard ratios (HR) with 95% confidence intervals (CI) for various patient characteristics comparing Ticagrelor versus placebo. The plot includes subgroups by age, sex, race, body mass index, geographic region, aspirin dose, baseline HbA1c, kidney function (eGFR), insulin use, history of angina, coronary artery disease status, PCI history and stent use, time since PCI or CABG, smoking status, and diabetes duration. The horizontal axis ranges from 'Ticagrelor Better' to 'Placebo Better' based on HR values.*
FDA Label Image

Figure_17 (Figure 17)

Figure_17 (Figure 17)
A Kaplan-Meier curve comparing cumulative percentage events over days from randomization between Ticagrelor 90 mg twice daily and placebo groups. The solid line represents Ticagrelor with 303 events in 5523 subjects (5.4% KM), and the dashed line represents placebo with 362 events in 5493 subjects (6.5% KM). The x-axis shows days from randomization, and the y-axis shows cumulative percentage.*
FDA Label Image

Figure_18 (Figure 18)

Figure_18 (Figure 18)
A forest plot chart depicting hazard ratios (HR) and 95% confidence intervals for various patient characteristics comparing Ticagrelor versus placebo. The chart includes subgroups by age, sex, race, weight, BMI, geographic region, diagnosis, and medical history, displaying treatment effects with a central vertical line marking no difference between Ticagrelor and placebo.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
A line graph showing cumulative percentage (%) of events over months from randomization comparing Ticagrelor and placebo groups. The x-axis represents months up to 54, and the y-axis shows cumulative percentage. The Ticagrelor group is represented by a solid line with higher cumulative events than the placebo group, shown with a dashed line. Numbers at risk for each group are listed below the x-axis over time.*
FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
A Kaplan-Meier cumulative percentage curve showing the comparison of events between Ticagrelor 90 mg twice daily (solid line) and placebo (dashed line) groups over 30+ days from randomization. The x-axis represents days from randomization and the y-axis represents cumulative percentage. A risk table with patient counts is displayed below the x-axis.*
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
A line graph comparing IPA (%) induced by 20µM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor shows a rapid and high increase in IPA reaching about 90%, Clopidogrel a moderate increase reaching around 50%, and Placebo remains near zero with slight increase over 8 hours.*
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
A line graph comparing the percent inhibition of platelet aggregation (IPA) induced by 20µM ADP over time (days) for Ticagrelor, Clopidogrel, and Placebo. The x-axis represents time in days, and the y-axis shows IPA percentage. A smaller inset graph shows IPA over hours for the same drugs.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
A forest plot chart titled 'Mean effect and 90% CI' comparing Ticagrelor and AR-C124910XX across intrinsic factors such as age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and hepatic impairment. The chart shows changes relative to reference with pharmacokinetic parameters Cmax and AUC represented by squares and triangles, respectively. Each factor indicates 'No dose adjustment' in the recommendation column.*
FDA Label Image

Figure_9 (Image 09)

Figure_9 (Image 09)
A forest plot chart illustrating the mean effect and 90% confidence interval of Ticagrelor dose interactions with various drugs. The chart compares the change relative to the interacting drug alone, showing data points for Cmax and AUC pharmacokinetic variables, along with labeled recommendations for dose adjustments or monitoring requirements.*
FDA Label Image

60 mg 60 Count Label (Image 60)

60 mg 60 Count Label (Image 60)
Label for Ticagrelor tablets 60 mg, oral dosage form, distributed by Oryza Pharmaceuticals, Inc. The label indicates 60 tablets per package, includes storage instructions (20° to 25°C), and states the product is manufactured by Sunshine Lake Pharma Co., Ltd. in China. The label features a barcode, NDC 72516-017, and a revision date of 10/2025.*
FDA Label Image

Logo (Logo0001 01)

Logo (Logo0001 01)
FDA Label Image

Logo0001-02 (Logo0001 02)

Logo0001-02 (Logo0001 02)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.